Carvedilol vs propranolol in treatment of portal hypertension in cirrhotic patients with oesophageal varices
| dc.contributor.author | Візір, Марина Олександрівна | |
| dc.contributor.author | Vizir, Maryna | |
| dc.contributor.author | Iipinge, Emilie | |
| dc.contributor.author | Визир, Марина Александровна | |
| dc.contributor.author | Iraqi, Hamza | |
| dc.date.accessioned | 2019-06-14T10:53:43Z | |
| dc.date.available | 2019-06-14T10:53:43Z | |
| dc.date.issued | 2019-05-01 | |
| dc.description.abstract | Portal hypertension occurs in most patient with liver cirrhosis. Carvedilol a non-selective beta-blocker with intrinsic alpha-1 blocker activity has a greater reduction of portal pressure in patients with portal hypertension than Propranolol. In almost 90% of patients with cirrhosis oesophageal varices can be found and about 30% of that varices are at risk of bleeding. The estimated death rate for first episode of variceal haemorrhage is 30-50%. | ru_RU |
| dc.identifier.citation | Vizir M. Carvedilol vs propranolol in treatment of portal hypertension in cirrhotic patients with oesophageal varices / М. Vizir, E. Iipinge, H. Iraqi // Инновационные подходы к диагностике и лечению терапевтических заболеваний : материалы республиканской юбилейной научно-практической конференции, Ташкент, 1–2 мая 2019 г. – Ташкент, 2019. – P. 24. | ru_RU |
| dc.identifier.uri | https://repo.knmu.edu.ua/handle/123456789/23476 | |
| dc.language.iso | en | ru_RU |
| dc.subject | Carvedilol | ru_RU |
| dc.subject | propranolol | ru_RU |
| dc.subject | oesophageal varices | ru_RU |
| dc.title | Carvedilol vs propranolol in treatment of portal hypertension in cirrhotic patients with oesophageal varices | ru_RU |
| dc.type | Thesis | ru_RU |